▽inotuzumab ozogamicin - PubMed - NCBI ●01/09 11:41 2025 1433 resultsInotuzumab ozogamicin in B-cell precursor acute lymphoblastic leukemia: efficacy, toxicity, and practical considerations.Rubinstein JD, O'Brien MM. Rubinstein JD, et al. Front Immunol. 2023 Aug 3;14:1237738. doi: 10.3389/fimmu.2023.1237738. eCollection 2023. Front Immunol. 2023. PMID: 37600823 Free PMC article. Review.Inotuzumab ozogamicin (InO) is an antibody drug conjugate c
▽epratuzumab - PubMed - NCBI ●01/09 09:57 Epratuzumab (humanised anti-CD22 antibody) in autoimmune diseases.Steinfeld SD, Youinou P. Steinfeld SD, et al. Expert Opin Biol Ther. 2006 Sep;6(9):943-9. doi: 10.1517/14712598.6.9.943. Expert Opin Biol Ther. 2006. PMID: 16918261 Review.Selective modulation of B cells has been recently achieved using a humanised monoclonal antibody against the B cell surface marker CD22. This antibody (epratuzu
▽pracinostat - PubMed - NCBI ●01/09 07:43 Pracinostat (SB939), a histone deacetylase inhibitor, suppresses breast cancer metastasis and growth by inactivating the IL-6/STAT3 signalling pathways.Chen J, Li N, Liu B, Ling J, Yang W, Pang X, Li T. Chen J, et al. Life Sci. 2020 May 1;248:117469. doi: 10.1016/j.lfs.2020.117469. Epub 2020 Feb 25. Life Sci. 2020. PMID: 32109485The novel histone deacetylase inhibitor pracinostat suppresses the
